CLGN

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

The Reporting Person is filing this Amendment No. 4 to Schedule 13D ("Amendment No. 4") to report his sale of 140,000 Ordinary Shares during the period from October 16, 2025 through November 19, 2025. Furthermore, since he last filed Amendment No. 3 to Schedule 13D on November 5, 2019, the Reporting Person's beneficial ownership has decreased materially. The Reporting Person holds the Ordinary Shares reported herein for investment purposes only. The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions. Except as described above, as of the filing of this Amendment No. 4, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares, or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's memorandum of association or articles of association or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing the ADSs to be delisted from the Nasdaq Capital Market or any other national securities exchange on which they may be listed in the future, or to cease to be authorized to be quoted in any inter-dealer quotation system of a registered national securities association in which they may be quoted in the future; (i) causing the ADSs to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.